1 min read
Add as a preferred source on GoogleOppenheimer Downgrades Dyne Over Small DYN-101 Trial Size
The firm cut its rating to Perform from Outperform, saying the study's size may weaken the significance of upcoming data.
Oppenheimer lowered its rating on Dyne Therapeutics to Perform from Outperform, pointing to the size of a trial for its myotonic dystrophy type 1 candidate as a potential limit on the significance of upcoming data.
The candidate, DYN-101, is also known as zeleciment basivarsen or z-basivarsen. Oppenheimer's concern was that the small study could weaken the significance of future results.
Enna Lee
ReporterEnna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.